Day 1:

Switching to Exemestane Achieves Superior Outcome Compared with 5 Years of Tamoxifen in Post-Menopausal Estrogen Receptor-Positive Breast Cancer

TEAM Trial: Tamoxifen/AI Sequencing as Effective as Continuous 5-Year AI Therapy

Do Bisphosphonates Protect against Breast Cancer?

Alcohol and Obesity Raise Risk of Breast Cancer Recurrence

Denosumab Outperforms Zoledronic Acid for Bone Protection in Breast Cancer Patients


Day 2:

Lapatinib Plus Trastuzumab Overcomes Trastuzumab Resistance in Metastatic HER2-Positive Breast Cancer

Dose Escalation of Fulvestrant Increases Time to Progression in Hormone Receptor–Positive Breast Cancer

Long-term Follow-up Reveals Favorable Effect of Tamoxifen on Recurrences in DCIS

Sorafenib Active in Metastatic Breast Cancer

BIG I-98 Trial: Adjusting for Selective Crossover in Analyses of Letrozole vs Tamoxifen


Day 3:

Fewer Lung Cancer Deaths Seen in Women with Breast Cancer on Anti-Estrogen Therapies

Sorafenib Good Partner for Chemotherapy in Advanced/Metastatic Breast Cancer

Adding Bevacizumab to Second-line Chemotherapy Prolongs Progression-Free Survival in Metastatic Breast Cancer

Update from AVADO Shows Adding Bevacizumab to Chemotherapy Improves Progression-Free Survival and Response Rates

Optimal Duration of Neoadjuvant Letrozole to Permit Breast Conservation >4 Months


Day 4:

Taxane-related Peripheral Neuropathy Associated with Improved Outcomes

Anthracyclines Plus Trastuzumab Slightly Better Than Taxane/Carboplatin/Trastuzumab but More Worrisome Toxicity

Moderate Risk Patients More Likely to Choose Contralateral Prophylactic Mastectomy

Concurrent Trastuzumab with Chemotherapy Optimal Regimen

Profile Including Clinical Data and Biologic Markers Predicts DFS